SMN1 and proximal spinal muscular atrophy: Much further work will be necessary to identify analytes on this list that can improve the understanding of SMN deficiency on cellular pathophysiology, or to develop a biomarker that can be valuable to the efficient performance of SMA treatment trials, whether of a specific SMN-enhancing agent or of a therapy targeting other steps of the disease cascade.